Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Bertilimumab Chosen as a Top Autoimmune/Anti-Inflammatory Projects to Watch PR Newswire NEW YORK and HERZLIYA PITUACH, Israel, Dec. 1, 2014 NEW...
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update PR Newswire VANCOUVER, Nov. 28, 2014 VANCOUVER, Nov. 28...
Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option Immune has raised now total gross proceeds of...
Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants Immune has raised total gross proceeds of $9.625...
Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock PR Newswire NEW YORK and...
Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference Immune developing personalized medicine drugs for...
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS PR Newswire VANCOUVER, Nov. 4, 2014 VANCOUVER, Nov. 4, 2014 /PRNewswire/ - iCo...
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program PR Newswire VANCOUVER, Oct. 22, 2014 VANCOUVER, Oct. 22, 2014 /PRNewswire/...
New Clinical Data Supports Development Of Bertilimumab In Both Ulcerative Colitis And Crohn's Disease Immune Pharmaceuticals Recently Initiated...
Immune Pharmaceuticals Initiates Phase II Clinical Trial In Ulcerative Colitis Company Recently Initiated Phase II in Bullous Pemphigoid PR...
Immune Pharmaceuticals Presenting At The 16th Annual Rodman & Renshaw Global Investment Conference, September 10, 2014 Immune Pharmaceuticals...
iCo Therapeutics Announces Second Quarter 2014 Financial Results PR Newswire VANCOUVER, Aug. 29, 2014 VANCOUVER, Aug. 29, 2014 /PRNewswire/ - iCo...
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results PR Newswire VANCOUVER, Aug. 19, 2014 VANCOUVER, Aug. 19, 2014 /PRNewswire/...
Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market PR Newswire CAMBRIDGE, Mass. and HERZLIYA-PITUACH, Israel...
Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지